NCT07326280 The Cold Ischemia Robot-assisted Partial Nephrectomy
| NCT ID | NCT07326280 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sun Yat-sen University |
| Condition | Renal Cell Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 310 participants |
| Start Date | 2024-01-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 310 participants in total. It began in 2024-01-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To establish evidence that cold ischemia, achieved through the use of ice slush, can improve the recovery from ischemia on the operated kidney in patients undergoing robot-assisted partial nephrectomy.
Eligibility Criteria
Inclusion Criteria: \- 18 to 80 years old; 2. Intending to perform robot-assisted partial nephrectomy Exclusion Criteria: * Anesthesiologist assessment: Patient unsuitable for general anesthesia; * Having severe cardiovascular and cerebrovascular diseases; * horseshoe kidney; * pregnant women
Contact & Investigator
Fangjian Zhou, professor
PRINCIPAL INVESTIGATOR
Sun Yat-sen University Cancer Center (SYSUCC)
Frequently Asked Questions
Who can join the NCT07326280 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Renal Cell Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07326280 currently recruiting?
Yes, NCT07326280 is actively recruiting participants. Contact the research team at zhoufj@sysucc.org.cn for enrollment information.
Where is the NCT07326280 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT07326280 clinical trial?
NCT07326280 is sponsored by Sun Yat-sen University. The principal investigator is Fangjian Zhou, professor at Sun Yat-sen University Cancer Center (SYSUCC). The trial plans to enroll 310 participants.